Drug Profile
Becaplermin biosimilar - BioSavita
Alternative Names: PDGF BB biosimilarLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BioSavita
- Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
- Mechanism of Action Platelet-derived growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetic foot ulcer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetic-foot-ulcer in USA (Topical)
- 06 May 2013 Research programme - becaplermin biosimilar - BioSavita is available for licensing as of 06 May 2013. http://biosavita.com/
- 02 May 2013 Early research in Diabetic foot ulcer in USA (Topical)